Abstract
Purpose
To compare the pharmacodynamic behaviour of vecuronium with that of ORG 9487. we measured the time-course of action of equipotent doses of ORG 9487 and vecuronium and investigated their mutual interaction when given in succession.
Methods
Sixty ASA I–II patients were anaesthetized with thiopentone, fentanyl halothane and nitrous oxide and assigned randomly to four groups. Each patient received an initial dose (ID) of either vecuronium (V) or ORG 9487 (O) followed by maintenance doses (MDn) of either V or O (ID/MD: O/O, V/O, O/V, and V/V). The time course of action was measured mechanomyographically, determining the duration until 25% recovery of the single twitch (DUR25).
Results
The onset time of an ID of ORG 9487 was shorter than that of an ID of vecuronium (96vs 203 sec. P < 0.001). The DUR25 of the ID of ORG 9487 was less than half that of vecuronium (10.7 ± 2.8 vs 28.8 ± 6.1 min, P< 0.001). The DUR25 of MD1 and MD2 of ORG 9487 were shorter than those of vecuronium (O/O: 7.3 ± 2.8 and 8.5 ± 2.4 mm. V/O: 12.7 ± 3.3 and 11.5 ± 3.5 min,vs O/V. 16.4 ± 4.5 and 20.6 ± 4.7 min: V/V: 18.8 ± 3.0 and 20.1 ± 3.8 min, respectively, P < 0.05). An ID of vecuronium prolonged the DUR25 of MD1 and MD2 of ORG 9487 (P < 0.05)
Conclusion
ORG 9487 is a muscle relaxant with a shorter duration of action than vecuronium. Maintenance doses of ORG 9487 are also shorter acting than roughly equipotent maintenance doses of vecuronium, irrespective of which relaxant is given initially.
Résumé
Objectif
Dans le but de comparer le comportement pharmacodynamique du vécur onium avec celui de l’ORG 9487, nous avons mesuré le décours temporel de l’activité de deux doses équipotentes d’ORG 9487 et de vécuronium et étudié leur interaction mutuelle lorsqu’ils sont administrés successivement.
Méthodes
Soixante patients ASA I et II anesthésiés au thiopental, fentanyl, halothane et protoxyde d’azote ont été répartis aléatoirement en quatre groupes. Chaque patient recevait une dose initiale (DI) de vécuronium (V) ou d’ORG 9487 (O) suíví par des doses d’entretien (DE) de V ou de O (DI/DE: O/O, V/O, O/V et V/V. Le décours temporel de l’activité était mesuré par mécanomyographie en déterminant l’intervalle de récupération de 25% du twitch (DUR25)
Résultats
Le début d’action d’une Dl d’ORG 9487 était plus court qu’une DI de vécuronium (96vs 203 s, P < 0.001). La DUR25 de la Dl d’ORG 9487 était la moitié de celle du vecuronium (10.7 ± 2,8vs 28.8 ± 6.1 min, P < 0.001). La DUR25 de la DE et de la DE2 de l’ORG 9487 était plus courte que celle du vécuronium (respectivement. O/O: 7.3 ± 2.8 et 8.5 ± 2.4 min; V/O: 12.7 ± 3.3 et 11.5 ± 3.5 min vs O/V: 16.4 ± 4.5 et 20.6 ± 4.7 min, V/V, 18.8 ± 3.0 et 20.1 ± 3.8 min. P < 0.05) Une DI de vécuronium prolongeait la DUR25 de la DE1 et de la DE2 de l’ORG 9487 (P < 0.05).
Conclusion
Le myorelaxant ORG 948/ possède une durée d’action plus courte que le vécuronium. Les doses d’entretien de l’ORG 9487 ont une durée d’action plus courte que des doses à peu presque équipotentes de vécuronium quel que soit le myorelaxant initial administré.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Wierda JMKH, Van den Broek L, Proost JH, Verbaan BW, Hennis PJ. Time course of action and endotracheal intubating conditions of Org 9487, a new shortacting steroidal muscle relaxant; a comparison with succinylcholine. Anesth Analg 1993; 77: 579–84.
Van den Broek L, Wierda JMKH, Smeulers NJ, Proost JH. Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. Br J Anaesth 1994; 73: 331–5.
Rowaan CJ, Vandenbrom RHG, Wierda JMKH. The relaxometer: a complete and comprehensive computer-controlled neuromuscular transmission measurement system developed for clinical research on muscle relaxants. J Clin Monit 1993; 9: 38–44.
Rashkovsky OM, Agoston S, Ket JM. Interaction between pancuronium bromide and vecuronium bromide. Br J Anaesth 1985; 57: 1063–6.
Kay B, Chestnut RJ, Sum Ping JST, Healy TEJ. Economy in the use of muscle relaxants. Vecuronium after pancuronium. Anaesthesia 1987; 42: 277–80.
Erkola O, Rautoma P, Meretoja OA. Mivacurium when preceded by pancuronium becomes a long-acting muscle relaxant. Anesthesiology 1996; 84: 562–5.
Kim DW, Joshi GP, White PF, Johnson ER. Interactions between mivacurium,rocuronium, and vecuronium during general anesthesia. Anesth Analg 1996; 83: 818–22.
Middleton CM, Pollard BJ, Healy TEJ, Kay B. Use of atracurium or vecuronium to prolong the action of tubocurarine. Br J Anaesth 1989; 62: 659–63.
Roberts SP, Ramsay TM, Healy TEJ, Wilson A, Pollard BJ. Extending a pipecuronium neuromuscular block. Increments of atracurium or vecuronium as an alternative to pipecuronium. Anaesthesia 1993; 48: 196–9.
Goudsouzian NG, Denman W, Matta E. Mivacurium after atracurium in children. Anesth Analg 1994; 79: 345–9.
Whalley DG, Lewis B, Bedocs NM. Recovery of neuromuscular function after atracurium and pancuronium maintenance of pancuronium block. Can J Anaesth 1994; 41: 31–5.
Paton WDM, Waud DR. The margin of safety of neuromuscular transmission. J Physiol 1967; 191: 59–90.
Fawcett WJ, Fauvel NJ, Feldman SA. Comparison of recovery index of rocuronium or vecuronium with simultaneously administered pancuronium in the isolated forearm. Anaesthesia 1993; 48: 200–1.
Wierda JMKH, Beaufort AM, Kleef UW, Smeulers NJ, Agoston S. Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. Can J Anaesth 1994; 41: 213–20.
Sohn YJ, Bencini AF, Scaf AHJ, Kersten UW, Agoston S. Comparative pharmacokinetics and dynamics of vecuronium and pancuronium in anesthesized patients. Anesth Analg 1986; 65: 233–9.
Lebowitz PW, Ramsey FM, Savarese JJ, Ali HH. Potentiation of neuromuscular blockade in man produced by combinations of pancuronium and metocurine or pancuronium and d-tubocurarine. Anesth Analg 1980; 59: 604–9.
Waud BE, Waud DR. Quantitative examination of the interaction of competitive neuromuscular blocking agents on the indirectly elicited muscle twitch. Anesthesiology 1984; 61: 420–7.
Waud BE, Waud DR. Interaction among agents that block end-plate depolarization competitively. Anesthesiology 1985; 63: 4–15.
Naguib M, Abdulatif M. Isobolographic and dose-response analysis of the interaction between pipecuronium and vecuronium. Br J Anaesth 1993; 71: 556–60.
Naguib M, Abdulatif M, Al-Ghamdi A, et al. Interactions between mivacurium and atracurium. Br J Anaesth 1994; 73: 484–9.
Naguib M. Neuromuscular effects of rocuronium bromide and mivacurium chloride administered alone and in combination. Anesthesiology 1994; 81: 388–95.
Ferres CJ, Mirakhur RK, Pandit SK, Clarke RSJ, Gibson FM. Dose-response studies with pancuronium, vecuronium and their combination. Br J Clin Pharmacol 1984; 18: 947–50.
Eshleman MR, Miller J. Muscle relaxant combinations. Semin Anesth 1995; 14: 264–72.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schiere, S., van den Brock, L., Proost, J.H. et al. Comparison of vecuronium with ORG 9487 and their interaction. Can J Anesth 44, 1138–1143 (1997). https://doi.org/10.1007/BF03013333
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03013333